Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
Aruna Das PradhanRobert J GlynnJean-Charles FruchartJean G MacFadyenElaine S ZaharrisBrendan M EverettStuart E CampbellRyu OshimaPierre AmarencoDirk J BlomEliot A BrintonRobert H EckelMarshall B ElamJoão S FelicioHenry N GinsbergAssen GoudevShun IshibashiJacob JosephTatsuhiko KodamaWolfgang KoenigLawrence A LeiterAlberto J LorenzattiBoris MankovskyNikolaus MarxBørge G NordestgaardDénes PállKausik K RayRaul Dias Dos Santos FilhoHandrean SoranAndrey SusekovMichal TenderaKoutaro YokoteNina P PaynterJulie E BuringPeter LibbyPaul M Ridkernull nullPublished in: The New England journal of medicine (2022)
Among patients with type 2 diabetes, mild-to-moderate hypertriglyceridemia, and low HDL and LDL cholesterol levels, the incidence of cardiovascular events was not lower among those who received pemafibrate than among those who received placebo, although pemafibrate lowered triglyceride, VLDL cholesterol, remnant cholesterol, and apolipoprotein C-III levels. (Funded by the Kowa Research Institute; PROMINENT ClinicalTrials.gov number, NCT03071692.).